JPRN-UMIN000001028已完成未知
Randomized Phase III Trial of Irinotecan plus Cisplatin vs. bi-weekly Irinotecan after S-1 failure for Patients with Advanced and Recurrent Gastric Cancer - Randomized Phase III Trial of Irinotecan plus Cisplatin vs. bi-weekly Irinotecan after S-1 failure for Patients with Advanced and Recurrent Gastric Cancer (TCOG GI-0801)
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 130
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.a patient who received transfusion, blood products, or hematopoietic growth factors such as G-CSF within 7 days prior to the registration 2.S-1+CPT-11 combination therapy as the first line chemotherapy 3. Advanced gastric cancer that refuses operation 4. History of severe drug allergic reaction 5.serious pleural effusion or ascites 6.serious Infectious disease 7. Watery diarrhea 8. Intestinal obstruction or Intestines paralysis 9. Intestinal fresh hemorrhage 10. With serious lung disease 11.administering atazanavir sulfate 12. Symptomatic brain metastasis 13. Active secondary cancer 14. cardiac disease 15. psychiatric disease or nervous disease 16. preganat or nursing patients and patients who may be pregnant 17. Decision as ineligible by principal investigator
研究者
相似试验
进行中（未招募）
1 期
Study comparing the standard administration of immunotherapy (IO) versus the same agent administered each three months in patients with metastatic cancer in response after 6 months of standard IOOncologic metastatic tumour (lung cancer (K), renal cell K (except IMDC favorable-risk treated TKI / immunotherapy [IO] combination), head and neck K, bladder K, triple negative breast K, Merkel K and melanoma, or hepatocellular carcinoma) in PR or CR (except for melanoma, only patients in partial response) after 6 months of standard IO treatment (monotherapy or previously in combination with other immunotherapy or chemotherapy or continuous combination with pemetrexed or bevacizumab or TKI).MedDRA version: 20.0Level: LLTClassification code 10025044Term: Lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10038407Term: Renal cell cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10067821Term: Head and neck cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10005003Term: Bladder cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10075566Term: Triple negative breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10053571Term: MelanomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10073071Term: Hepatocellular carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10064025Term: Merkel cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cystEUCTR2021-000615-23-FRICANCER646
进行中（未招募）
不适用
Multicenter phase III randomized study of cisplatin and etoposide with or without bevacizumab as first-line treatment in extensive stage (ED) small cell lung cancer (SCLC) - NDEUCTR2007-007949-13-ITGRUPPO ONCOLOGICO ITALIANO DI RICERCA
进行中（未招募）
不适用
A Phase 3 Randomized Trial of Concurrent Cisplatin And Radiotherapy With or Without OncoVEXGM-CSF in Previously Untreated Patients with Locally Advanced Squamous Cell Carcinoma of the Head and NeckEUCTR2010-019071-29-GBBioVex, Inc.580
进行中（未招募）
不适用
A Phase III Randomized, Controlled Trial of Myocet, Trastuzumab and Paclitaxel versus Trastuzumab and Paclitaxel for First line Therapy of Metastatic Breast CancerHER2+ Metastatic Breast CancerMedDRA version: 8.1Level: lltClassification code 10027475EUCTR2005-006109-19-DESopherion Therapeutics, Inc.332
进行中（未招募）
不适用
A Phase III Randomized, Controlled Trial of Myocet, Trastuzumab and Paclitaxel versus Trastuzumab and Paclitaxel for First line Therapy of Metastatic Breast Cancer - NDHER2+ metastatic breast cancerMedDRA version: 9.1Level: LLTClassification code 10006279Term: Breast neoplasmEUCTR2005-006109-19-ITSOPHERION THERAPEUTICS, INC.600